Multikine is under clinical development by CEL-SCI and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Multikine’s likelihood of approval (LoA) and phase transition for Head And Neck Cancer Squamous Cell Carcinoma took place on 10 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 10 Oct 2022 increased Multikine’s LoA and PTSR for Oral Cavity (Mouth) Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Multikine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Multikine overview

Multikine (Leukocyte Interleukin) is under development for the treatment of squamous cell carcinoma of the head and neck including oral cavity and cervical dysplasia in HIV/HPV co-infected women. The drug candidate is administered through the parenteral route as injection. The therapeutic candidate is a natural mixture of pro-inflammatory cytokines and chemokines (containing: IL-2, IL-1 beta, IFN-gamma, TNF-alpha and GM-CSF). It was also under development for the treatment of peri-anal warts (condyloma acuminata), chemotherapy effects due to head and neck or soft palate cancer, prostate cancer and radiation toxicity.

CEL-SCI overview

CEL-SCI is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer, autoimmune, and infectious diseases. Its core capabilities include drug discovery, research, development and manufacture of compound biological substances. CEL-SCI’s lead candidate, Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines, CEL-2000 and CEL-4000 for rheumatoid arthritis using Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Fairfax, Virginia, the US.

Quick View Multikine LOA Data

Report Segments
  • Innovator
Drug Name
  • Multikine
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Infectious Disease
  • Oncology
  • Toxicology
  • Women’s Health
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.